α‐L‐iduronidase mutations (Q70X and P533R) associate with a severe Hurler phenotype

Hamish S. Scott, Tom Litjens, Paul V. Nelson, Doug A. Brooks, John J. Hopwood, C. Phillip Morris

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

Mucopolysaccharidosis type I (MPS‐I) is an autosomal recessive genetic disease caused by a deficiency of the glycosidase α‐L‐iduronidase which is required for the lysosomal degradation of the glycosaminoglycans heparan sulfate and dermatan sulfate. Patients with MPS‐I store forms of these partially degraded glycosaminoglycans in their lysosomes. MPS‐I patients present with a wide range of clinical phenotypes, which makes prognostic predictions and genetic counselling difficult, therefore impeding the selection and evaluation of patients undergoing experimental therapy, such as bone marrow transplantation. We report the presence of two mutations, one that introduces a stop codon at position 70 (Q70X), and the other that alters the proline at position 533 to an arginine (P533R) in the 653 amino acid α‐L‐iduronidase protein. These mutations were originally detected by chemical cleavage and then by direct PCR sequencing. Allele specific oligonucleotides were used to detect the mutations in a group of 73 MPS‐I patients and Q70X was found to account for 15% of all MPS‐I alleles and P533R for 3% of MPS‐I alleles. Both mutations are associated with an extremely severe clinical phenotype in homozygotes. MPS‐I patients heterozygous for either mutation may have a wide range of clinical phenotypes. We have now described three mutations, W402X (Scott et al., 1992c), Q70X, and P533R totalling 53% of MPS‐I alleles which together define 28% of MPS‐I genotypes. © 1992 Wiley‐Liss, Inc.

LanguageEnglish
Pages333-339
Number of pages7
JournalHuman Mutation
Volume1
Issue number4
DOIs
Publication statusPublished - 1 Jan 1992
Externally publishedYes

Keywords

  • Lysosomal glycosidase
  • Lysosomal storage disorder
  • Scheie syndrome

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)

Cite this

Scott, H. S., Litjens, T., Nelson, P. V., Brooks, D. A., Hopwood, J. J., & Morris, C. P. (1992). α‐L‐iduronidase mutations (Q70X and P533R) associate with a severe Hurler phenotype. Human Mutation, 1(4), 333-339. https://doi.org/10.1002/humu.1380010412
Scott, Hamish S. ; Litjens, Tom ; Nelson, Paul V. ; Brooks, Doug A. ; Hopwood, John J. ; Morris, C. Phillip. / α‐L‐iduronidase mutations (Q70X and P533R) associate with a severe Hurler phenotype. In: Human Mutation. 1992 ; Vol. 1, No. 4. pp. 333-339.
@article{d6516f09013c41138ee654aeb3c27cc0,
title = "α‐L‐iduronidase mutations (Q70X and P533R) associate with a severe Hurler phenotype",
abstract = "Mucopolysaccharidosis type I (MPS‐I) is an autosomal recessive genetic disease caused by a deficiency of the glycosidase α‐L‐iduronidase which is required for the lysosomal degradation of the glycosaminoglycans heparan sulfate and dermatan sulfate. Patients with MPS‐I store forms of these partially degraded glycosaminoglycans in their lysosomes. MPS‐I patients present with a wide range of clinical phenotypes, which makes prognostic predictions and genetic counselling difficult, therefore impeding the selection and evaluation of patients undergoing experimental therapy, such as bone marrow transplantation. We report the presence of two mutations, one that introduces a stop codon at position 70 (Q70X), and the other that alters the proline at position 533 to an arginine (P533R) in the 653 amino acid α‐L‐iduronidase protein. These mutations were originally detected by chemical cleavage and then by direct PCR sequencing. Allele specific oligonucleotides were used to detect the mutations in a group of 73 MPS‐I patients and Q70X was found to account for 15{\%} of all MPS‐I alleles and P533R for 3{\%} of MPS‐I alleles. Both mutations are associated with an extremely severe clinical phenotype in homozygotes. MPS‐I patients heterozygous for either mutation may have a wide range of clinical phenotypes. We have now described three mutations, W402X (Scott et al., 1992c), Q70X, and P533R totalling 53{\%} of MPS‐I alleles which together define 28{\%} of MPS‐I genotypes. {\circledC} 1992 Wiley‐Liss, Inc.",
keywords = "Lysosomal glycosidase, Lysosomal storage disorder, Scheie syndrome",
author = "Scott, {Hamish S.} and Tom Litjens and Nelson, {Paul V.} and Brooks, {Doug A.} and Hopwood, {John J.} and Morris, {C. Phillip}",
year = "1992",
month = "1",
day = "1",
doi = "10.1002/humu.1380010412",
language = "English",
volume = "1",
pages = "333--339",
journal = "Human mutation",
issn = "1059-7794",
publisher = "Wiley-Liss Inc.",
number = "4",

}

Scott, HS, Litjens, T, Nelson, PV, Brooks, DA, Hopwood, JJ & Morris, CP 1992, 'α‐L‐iduronidase mutations (Q70X and P533R) associate with a severe Hurler phenotype', Human Mutation, vol. 1, no. 4, pp. 333-339. https://doi.org/10.1002/humu.1380010412

α‐L‐iduronidase mutations (Q70X and P533R) associate with a severe Hurler phenotype. / Scott, Hamish S.; Litjens, Tom; Nelson, Paul V.; Brooks, Doug A.; Hopwood, John J.; Morris, C. Phillip.

In: Human Mutation, Vol. 1, No. 4, 01.01.1992, p. 333-339.

Research output: Contribution to journalArticle

TY - JOUR

T1 - α‐L‐iduronidase mutations (Q70X and P533R) associate with a severe Hurler phenotype

AU - Scott, Hamish S.

AU - Litjens, Tom

AU - Nelson, Paul V.

AU - Brooks, Doug A.

AU - Hopwood, John J.

AU - Morris, C. Phillip

PY - 1992/1/1

Y1 - 1992/1/1

N2 - Mucopolysaccharidosis type I (MPS‐I) is an autosomal recessive genetic disease caused by a deficiency of the glycosidase α‐L‐iduronidase which is required for the lysosomal degradation of the glycosaminoglycans heparan sulfate and dermatan sulfate. Patients with MPS‐I store forms of these partially degraded glycosaminoglycans in their lysosomes. MPS‐I patients present with a wide range of clinical phenotypes, which makes prognostic predictions and genetic counselling difficult, therefore impeding the selection and evaluation of patients undergoing experimental therapy, such as bone marrow transplantation. We report the presence of two mutations, one that introduces a stop codon at position 70 (Q70X), and the other that alters the proline at position 533 to an arginine (P533R) in the 653 amino acid α‐L‐iduronidase protein. These mutations were originally detected by chemical cleavage and then by direct PCR sequencing. Allele specific oligonucleotides were used to detect the mutations in a group of 73 MPS‐I patients and Q70X was found to account for 15% of all MPS‐I alleles and P533R for 3% of MPS‐I alleles. Both mutations are associated with an extremely severe clinical phenotype in homozygotes. MPS‐I patients heterozygous for either mutation may have a wide range of clinical phenotypes. We have now described three mutations, W402X (Scott et al., 1992c), Q70X, and P533R totalling 53% of MPS‐I alleles which together define 28% of MPS‐I genotypes. © 1992 Wiley‐Liss, Inc.

AB - Mucopolysaccharidosis type I (MPS‐I) is an autosomal recessive genetic disease caused by a deficiency of the glycosidase α‐L‐iduronidase which is required for the lysosomal degradation of the glycosaminoglycans heparan sulfate and dermatan sulfate. Patients with MPS‐I store forms of these partially degraded glycosaminoglycans in their lysosomes. MPS‐I patients present with a wide range of clinical phenotypes, which makes prognostic predictions and genetic counselling difficult, therefore impeding the selection and evaluation of patients undergoing experimental therapy, such as bone marrow transplantation. We report the presence of two mutations, one that introduces a stop codon at position 70 (Q70X), and the other that alters the proline at position 533 to an arginine (P533R) in the 653 amino acid α‐L‐iduronidase protein. These mutations were originally detected by chemical cleavage and then by direct PCR sequencing. Allele specific oligonucleotides were used to detect the mutations in a group of 73 MPS‐I patients and Q70X was found to account for 15% of all MPS‐I alleles and P533R for 3% of MPS‐I alleles. Both mutations are associated with an extremely severe clinical phenotype in homozygotes. MPS‐I patients heterozygous for either mutation may have a wide range of clinical phenotypes. We have now described three mutations, W402X (Scott et al., 1992c), Q70X, and P533R totalling 53% of MPS‐I alleles which together define 28% of MPS‐I genotypes. © 1992 Wiley‐Liss, Inc.

KW - Lysosomal glycosidase

KW - Lysosomal storage disorder

KW - Scheie syndrome

UR - http://www.scopus.com/inward/record.url?scp=0027018480&partnerID=8YFLogxK

U2 - 10.1002/humu.1380010412

DO - 10.1002/humu.1380010412

M3 - Article

VL - 1

SP - 333

EP - 339

JO - Human mutation

T2 - Human mutation

JF - Human mutation

SN - 1059-7794

IS - 4

ER -

Scott HS, Litjens T, Nelson PV, Brooks DA, Hopwood JJ, Morris CP. α‐L‐iduronidase mutations (Q70X and P533R) associate with a severe Hurler phenotype. Human Mutation. 1992 Jan 1;1(4):333-339. https://doi.org/10.1002/humu.1380010412